Recent Updates
Recently added Catalysts
SIBN Positive Sentiment

SI-BONE To Present at Piper Sandler 37th Annual Healthcare Conference on December 2, 2025

Key Takeaway: SI-BONE, Inc. announced its participation in the Piper Sandler 37th Annual Healthcare Conference, scheduled for December 2, 2025. The event will feature a fireside chat with management, providing an opportunity for investors to engage. SI-BONE is recognized for its advancements in treating sacropelvic disorders and has a robust clinical evidence base.
Price reaction · baseline $18.36 (2025-11-18 close) · hit after-hours · clean, no other SIBN news in the window
day 0 close · peak
+1.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • SI-BONE is participating in a notable healthcare conference.
  • The company has a strong history of innovation in surgical treatments.
  • Management will engage with investors through a fireside chat.

Full Press Release Details

SANTA CLARA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler 37thAnnual Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Tuesday, December 2, 2025, at 9:00 a.m. Pacific Time/ 12:00 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by registering at this link:SIBN Investors. Live audio of the webcast will be available on the “Investors” section of the company’s website at:www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in developing unique technologies for surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009 with the iFuse Implant System®, SI-BONE has supported over 4,900 physicians in performing a total of over 135,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies with over 180 peer reviewed publications including four randomized controlled trials. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic and sacropelvic fixation and pelvic trauma.
For additional information on the company or the products, including risks and benefits, please visitwww.si-bone.com.
SI-BONE,Sacropelvic Solutions,iFuse Implant System®, iFuse Bedrock Granite,andiFuse TORQ, are registered trademarks, andiFuse 3D, iFuse TORQ TNT, andiFuse INTRAare trademarks of SI-BONE, Inc. ©2025 SI-BONE, Inc. All Rights Reserved.

Frequently Asked Questions

When is SI-BONE's presentation at the conference?

SI-BONE will present at the Piper Sandler conference on December 2, 2025.

How can investors listen to the conference call?

Investors can register to listen to the conference call via the company's website.

What is the focus of SI-BONE's technologies?

SI-BONE focuses on surgical treatments for sacropelvic disorders.

What is the iFuse Implant System?

The iFuse Implant System is a minimally invasive solution pioneered by SI-BONE for SI joint surgery.

Last updated: Nov 18, 2025